慢性乙型肝炎患者如何获得临床治愈

doi:10.3969/j.issn.1672-5069.2016.03.001

Abstract

Chen Xinyue,Liu Yali. How patients with hepatitis B get really recovered[J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2016, 19(3): 257-260.

[1] Lozano R，Naghavi M，Foreman K，et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010:a systematic analysis for the Global Burden of Disease Study 2010. Lancet，2012，380（9859）:2095-2128.
[2] Wang FS，Fan JG，Zhang Z et al. The global burden of liver disease:the major impact of China. Hepatology. 2014，60（6）: 2099-2108.
[3] 中华医学会肝病学分会和感染病学分会. 慢性乙型肝炎防治指南（2015更新版）. 实用肝脏病杂志，2016，19（3）:Ⅴ-XXⅢ.
[4] 陈新月，柳雅立. 干扰素与核苷（酸）类似物联合治疗开创HBsAg转阴之路. 传染病信息，2015，28（5）:262-265.
[5] Kefalakes H，Jochum C，Hilgard G，et al. Decades after recovery from hepatitis B and HBsAg clearance the CD8（+） T cell response against HBV core is nearly undetectable. J Hepatol，2015，63（1）:13-19.
[6] 张欣欣. 乙型肝炎病毒标志物临床意义的新认识. 中华肝脏病杂志，2011，19（11）:801-802.
[7] Reijnders JG，Janssen HL. Relapse of chronic hepatitis B after discontinuation of nucleos（t）ide analogs:is the glass half full or half empty. Hepatology，2013，58（6）:1885-1887.
[8] 吴迪，宁琴. 2014年慢性病毒性肝炎临床诊疗进展. 实用肝脏病杂志，2015，18（1）:10-14.
[9] 庄辉，翁心华. 核苷（酸）类似药物治疗慢性乙型肝炎停药的探讨. 中国病毒病杂志，2013，23（4）:241-244.
[10] European Association for Study of L. EASL recommendations on treatment of hepatitis C 2015. J Hepatol，2015，63（1）:199-236.
[11] Chelbi-Alix MK，Wietzerbin J. Interferon，a growing cytokine family:50 years of interferon research. Biochimie，2007，89（6-7）: 713-718.
[12] Tan AT，Hoang LT，Chin D，et al. Reduction of HBV replication prolongs the early immunological response to IFN alpha therapy. J Hepatol，2014，60（1）:54-61.
[13] Micco L，Peppa D，Loggi E，et al. Differential boosting of innate and adaptive antiviral responses during pegylated-interferon-alpha therapy of chronic hepatitis B. J Hepatol，2013，58（2）:225-233.
[14] Thimme R，Dandri M. Dissecting the divergent effects of interferon-alpha on immune cells:time to rethink combination therapy in chronic hepatitis B. J Hepatol，2013，58（2）:205-209.
[15] Lau GK，Piratvisuth T，Luo KX，et al. Peginterferon alfa-2a，lamivudine，and the combination for HBeAg-positive chronic hepatitis B. N Engl J Med，2005，352（26）:2682-2695.
[16] Janssen HL，van Zonneveld M，Senturk H，et al. Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B:a randomised trial. Lancet，2005，365（9454）:123-129.
[17] Cao ZH，Ma LN，Zhang HW，et al. Extended treatment with peginterferon alpha-2a in combination with lamivudine or adefovir for 96 weeks yields high rates of HBeAg and HBsAg seroconversion. J Dig Dis，2013，14（8）:446-450.
[18] Ning Q，Han M，Sun Y，et al. Switching from entecavir to PegIFN alfa-2a in patients with HBeAg-positive chronic hepatitis B:a randomised open-label trial（OSST trial）. J Hepatol，2014，61（4）:777-784.
[19] Takkenberg RB，Jansen L，de Niet A，et al. Baseline hepatitis B surface antigen（HBsAg） as predictor of sustained HBsAg loss in chronic hepatitis B patients treated with pegylated interferon-alpha
2a and adefovir. Antivir Ther，2013，18（7）:895-904.
[20] Marcellin P，Ahn SH，Ma X，et al. Combination of tenofovir disoproxil fumarate and peginterferon alpha-2a increases loss of hepatitis B surface antigen in patients with chronic hepatitis B. Gastroenterology，2016，150（1）:134-144，e110.
[21] Hu P，Jia S，Zhang W，et al. A multi-center randomized study on the efficacy and safety of switching to peginterferon alpha-2a （40KD） for 48 or 96 weeks in HBeAg positive CHB patients with a prior NUC history for 1 to 3 years:an interim analysis of NEW SWITCH study. Hepatology，2014，60:1273a-1274a.

How patients with hepatitis B get really recovered

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments

[1]	chronic hepatitis B Zhu Lingyun, Zhang Maohai Cui Shasha, et al.. Serum IL-12 and IL-18 levels as well as peripheral blood mononuclear cell FOXp3 in patients with [J]. Journal of Practical Hepatology, 2019, 22(6): 816-819.
[2]	Shi Yingying, Wang Yuanxi.. Impact of combination telbivudine and adefovir dipivoxil on renal functions in the treatment of patients with chronic hepatitis B [J]. Journal of Practical Hepatology, 2019, 22(6): 820-823.
[3]	Min Feng, Huang Wenqi, Wu Weibing, et al.. Implications of serum adipocytokine levels in patients with chronic hepatitis B [J]. Journal of Practical Hepatology, 2019, 22(6): 824-827.
[4]	patients with chronic hepatitis B Zhang Yingming, Shen Shuang, Tian Fei, et al.. Prediction of response to peginterferon alfa-2a by blood IFNL4 and IL-28B gene polymorphisms in [J]. Journal of Practical Hepatology, 2019, 22(6): 828-831.
[5]	chronic hepatitis B virus carriers Wu Haiyi, Chen Jianxin.. Diagnostic efficacy of four non-invasive diagnostic models in evaluating significant liver fibrosis in [J]. Journal of Practical Hepatology, 2019, 22(6): 832-835.
[6]	Ma Liying, Shen Lijuan.. Efficacy and safety of tenofovir in the treatment of pregnant women with high HBV DNA loads [J]. Journal of Practical Hepatology, 2019, 22(6): 836-839.
[7]	Li Chuanjie, Xu Jing, Wang Liangliang, et al.. Changes of serum HBsAg levels in patients with chronic hepatitis B receiving entecavir treatment [J]. Journal of Practical Hepatology, 2019, 22(6): 928-929.
[8]	Du Keye, Yang Dongliang, Liu Jia. Regulatory T cells in hepatitis B [J]. Journal of Practical Hepatology, 2019, 22(5): 613-616.
[9]	Liao Guichan, Peng Jie, Zhang Xiaoyong. Roles of hepatocytes in intrinsic innate immunity in control of hepatits B virus infection [J]. Journal of Practical Hepatology, 2019, 22(5): 617-619.
[10]	Zhao Xieshan, Wu Chunrong, Wang Chunfeng, et al. Preliminary study on the efficacy of combination of tenofovir and Anluo Huaxian pill in the treatment of patients with HBeAg-negative chronic hepatitis B [J]. Journal of Practical Hepatology, 2019, 22(5): 644-647.
[11]	Tu Jiexia, Wang An’na, Liao Ruoxi. Comparative study of interferon alpha -2b and peginterferon alpha -2a in the treatment of patients with chronic hepatitis B [J]. Journal of Practical Hepatology, 2019, 22(5): 648-651.
[12]	Gao Wei, Hou Yong. Diagnostic efficacy of hepatic fibrosis by liver stiffness measurement in patients with chronic hepatitis B [J]. Journal of Practical Hepatology, 2019, 22(5): 652-655.
[13]	Zhu Yucheng, Yan Jiawei, Sun Jingkun, et al. Serum diamine oxidase level in patients with hepatitis B-induced acute-on-chronic liver failure [J]. Journal of Practical Hepatology, 2019, 22(5): 672-675.
[14]	Zhang Mei, Shi Xiuying, Li Linjuan, et al. Hepatic expression of interferon inducible protein -10 in patients with hepatitis B liver cirrhosis and hepatogenic diabetes mellitus [J]. Journal of Practical Hepatology, 2019, 22(5): 688-691.
[15]	Han Meiling, Chen Ping. Antiviral therapy in patients with liver cirrhosis and thrombocytopenia [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(4): 466-469.